117 related articles for article (PubMed ID: 38141473)
21. The development and validation of a comorbidity index for prostate cancer among Black men.
Fleming ST; Pearce KA; McDavid K; Pavlov D
J Clin Epidemiol; 2003 Nov; 56(11):1064-75. PubMed ID: 14614997
[TBL] [Abstract][Full Text] [Related]
22. Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting.
Lu CY; Barratt J; Vitry A; Roughead E
J Clin Epidemiol; 2011 Feb; 64(2):223-8. PubMed ID: 21172602
[TBL] [Abstract][Full Text] [Related]
23. Prediction Ability of Charlson, Elixhauser, and Rx-Risk Comorbidity Indices for Mortality in Patients with Hip Fracture. A Danish Population-Based Cohort Study from 2014 - 2018.
Vesterager JD; Madsen M; Hjelholt TJ; Kristensen PK; Pedersen AB
Clin Epidemiol; 2022; 14():275-287. PubMed ID: 35299726
[TBL] [Abstract][Full Text] [Related]
24. An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts.
Gedeborg R; Sund M; Lambe M; Plym A; Fredriksson I; Syrjä J; Holmberg L; Robinson D; Stattin P; Garmo H
Epidemiology; 2021 Jul; 32(4):607-615. PubMed ID: 33935137
[TBL] [Abstract][Full Text] [Related]
25. Improved prediction of long-term, other cause mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
Westerberg M; Irenaeus S; Garmo H; Stattin P; Gedeborg R
PLoS One; 2024; 19(1):e0296804. PubMed ID: 38236934
[TBL] [Abstract][Full Text] [Related]
27. (Dis)concordance of comorbidity data and cancer status across administrative datasets, medical charts, and self-reports.
Sheriffdeen A; Millar JL; Martin C; Evans M; Tikellis G; Evans SM
BMC Health Serv Res; 2020 Sep; 20(1):858. PubMed ID: 32917193
[TBL] [Abstract][Full Text] [Related]
28. Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study.
Holvik K; Hjellvik V; Karlstad Ø; Gunnes N; Hoff M; Tell GS; Meyer HE
BMJ Open; 2022 May; 12(5):e057823. PubMed ID: 35501100
[TBL] [Abstract][Full Text] [Related]
29. Effect of external variables on the performance of the geriatric comorbidity score derived from prescription claims in the community-dwelling elderly.
Béland SG; Tannenbaum C; Ducruet T; Préville M; Berbiche D; Moride Y
Drugs Aging; 2012 Nov; 29(11):891-7. PubMed ID: 23109256
[TBL] [Abstract][Full Text] [Related]
30. Construction of a comorbidity index for prostate cancer patients linking state cancer registry with inpatient and outpatient data.
Xiao H; Tan F; Goovaerts P; Ali A; Adunlin G; Huang Y; Gwede C
J Registry Manag; 2013; 40(4):159-64. PubMed ID: 24625768
[TBL] [Abstract][Full Text] [Related]
31. Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts.
Quail JM; Lix LM; Osman BA; Teare GF
BMC Health Serv Res; 2011 Jun; 11():146. PubMed ID: 21663672
[TBL] [Abstract][Full Text] [Related]
32. Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012).
Diaz A; Baade PD; Valery PC; Whop LJ; Moore SP; Cunningham J; Garvey G; Brotherton JML; O'Connell DL; Canfell K; Sarfati D; Roder D; Buckley E; Condon JR
PLoS One; 2018; 13(5):e0196764. PubMed ID: 29738533
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
[TBL] [Abstract][Full Text] [Related]
34. Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset.
Ruseckaite R; Beckmann K; O'Callaghan M; Roder D; Moretti K; Zalcberg J; Millar J; Evans S
BMC Res Notes; 2016 Jan; 9():37. PubMed ID: 26801762
[TBL] [Abstract][Full Text] [Related]
35. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of a Medicines Comorbidity Index for older people.
Narayan SW; Nishtala PS
Eur J Clin Pharmacol; 2017 Dec; 73(12):1665-1672. PubMed ID: 28894902
[TBL] [Abstract][Full Text] [Related]
37. Identifying new-onset conditions and pre-existing conditions using lookback periods in Australian health administrative datasets.
Palamuthusingam D; Ratnayake G; Kuenstner K; Hawley CM; Pascoe EM; Jose MD; Johnson DW; Fahim M
Int J Qual Health Care; 2021 Feb; 33(1):. PubMed ID: 33216903
[TBL] [Abstract][Full Text] [Related]
38. Is there an optimal comorbidity index for prostate cancer?
Alibhai SM; Leach M; Tomlinson GA; Krahn MD; Fleshner NE; Naglie G
Cancer; 2008 Mar; 112(5):1043-50. PubMed ID: 18286512
[TBL] [Abstract][Full Text] [Related]
39. A Pharmaceutical Dispensing-based Index of Mortality Risk From Long-term Conditions Performed as well as Hospital Record-based Indices.
Stanley J; Doughty RN; Sarfati D
Med Care; 2020 Feb; 58(2):e9-e16. PubMed ID: 31568163
[TBL] [Abstract][Full Text] [Related]
40. Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database.
Lee C; Light A; Alaa A; Thurtle D; van der Schaar M; Gnanapragasam VJ
Lancet Digit Health; 2021 Mar; 3(3):e158-e165. PubMed ID: 33549512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
